Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and chemotherapies; thus, demand is high for safer, more-efficacious drugs. In the first line, FOLFIRINOX and Celgene’s Abraxane with gemcitabine therapy have emerged as alternative treatment strategies, while in the second line, Merrimack’s Onivyde appears to be a gaining traction. These therapies offer only modest survival benefits (overall survival is less than one year). Although current treatment is dominated by chemotherapies, upcoming targeted therapies, including AstraZeneca / Merck’s Lynparza, are expected to be better-tolerated options.

Questions answered:

  • What are the sizes of the U.S., EU5, and Japanese pancreatic cancer and PNET drug-treatable patient populations? How will drug-treatment rates change over our ten-year forecast period?
  • How are patients with pancreatic cancer and PNETs treated in the markets under study? What are interviewed experts’ insights on current treatment options?
  • What clinical needs remain unfulfilled, and which needs will be addressed by the end of our ten-year forecast period?
  • What are the key emerging therapies in development for pancreatic cancer and PNETs? What sales / uptake could these therapies secure in the pancreatic cancer market? What does the early-phase pipeline look like?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Pancreatic Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • COVID-19
      • Key Findings
        • Pancreatic Cancer - Key Findings
      • Key Updates
        • October 2020
        • December 2019
        • August 2019
        • June 2019
      • Market Outlook
        • Key Findings
          • Market Share of Drug Classes for Pancreatic Cancer: 2018
          • Market Share of Drug Classes for Pancreatic Cancer: 2028
          • Drug-Treatable Population Share and Major-Market Sales Share in Pancreatic Cancer: 2018
          • Drug-Treatable Population Share and Major-Market Sales Share in Pancreatic Cancer: 2028
          • Pancreatic Cancer SWOT Analysis
        • COVID-19: Areas of Potential Forecast Impact
          • Market Drivers and Constraints
            • What Factors Are Driving the Market for Pancreatic Cancer?
            • What Factors Are Constraining the Market for Pancreatic Cancer?
            • Major-Market Sales of Key Therapies in the Pancreatic Cancer Market: 2018-2028
            • Major-Market Sales for Pancreatic Cancer, by Region: 2018-2028
            • Major-Market Sales for Pancreatic Cancer, by Population Segment: 2018-2028
          • Segment-Specific Trends
            • Key Regimens' Share of Major-Market Sales for First-Line Metastatic Pancreatic Cancer: 2018 vs. 2028
            • Key Regimens' Share of Major-Market Sales for Second-Line Metastatic Pancreatic Cancer: 2018 vs. 2028
        • Forecast
          • Market Forecast Assumptions - Pancreatic Cancer (2018-2028) - December 2019
          • Market Forecast Dashboard - Pancreatic Cancer (2018-2028) - December 2019
        • Etiology and Pathophysiology
          • Disease Overview
            • Tumor Invasion from the Head of the Pancreas into the Small Intestine
            • Common Metastatic Sites in Pancreatic Cancer
            • Etiology
            • Genetic Risk Factors for Developing Pancreatic Cancer
            • Nonmodifiable and Modifiable Risk Factors for Developing Pancreatic Cancer
            • Disease Pathophysiology of Pancreatic Adenocarcinoma
            • Development of Pancreatic Adenocarcinoma
            • Disease Pathophysiology of Pancreatic Neuroendocrine Tumors (PNETs)
            • Tumor, Node, Metastasis Status Staging System for Pancreatic Cancer
            • Stage Grouping System for Pancreatic Cancer
            • Grading System for Pancreatic Neuroendocrine Tumors (PNETs)
          • Key Pathways and Drug Targets
            • Signaling Pathways Implicated in the Development of Pancreatic Cancer
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Incidence of Pancreatic Cancer
              • Number of Diagnosed Incident Cases of Pancreatic Cancer in the Major Pharmaceutical Markets by Subtype: 2018-2028
              • Disease Definition
              • Methods
              • Sources Used for Stage Distribution of Pancreatic Cancer
              • Number of Diagnosed Incident Cases of Pancreatic Exocrine Cancer in the Major Pharmaceutical Markets by Stage at Diagnosis: 2018-2028
              • Number of Diagnosed Incident Cases of Pancreatic Neuroendocrine Tumors in the Major Pharmaceutical Markets by Stage at Diagnosis: 2018-2028
              • Disease Definition
              • Methods
              • Sources Used for Recurrent Incidence of Pancreatic Cancer
              • Recurrent Incident Cases of Pancreatic Cancer: 2018-2028
              • Sources Used for Drug-Treatable Populations of Pancreatic Cancer
              • Pancreatic Exocrine Cancer Patient Flow
              • Pancreatic Neuroendocrine Tumors Patient Flow
              • Drug-Treatable Cases of Pancreatic Cancer: 2018-2028
              • Drug-Treated Cases of Pancreatic Cancer: 2018-2028
          • Current Treatment
            • Key Findings
              • Expert Insight
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Pancreatic Cancer
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drugs or Drug Classes Used for Pancreatic Adenocarcinoma
              • Mechanism of Action of Key Current Drugs or Drug Classes Used for Pancreatic Neuroendocrine Tumors
              • Current Treatments Used for Pancreatic Adenocarcinoma
              • Current Treatments Used for Pancreatic Neuroendocrine Tumors
              • Market Events Impacting the Use of Key Current Therapies for Pancreatic Cancer
              • Advantages and Disadvantages of Abraxane
              • Key Results from Select Clinical Trials Investigating Abraxane for the Treatment of Pancreatic Adenocarcinoma
              • Ongoing Clinical Development of Abraxane
              • Expert Insight: Abraxane
              • Advantages and Disadvantages of Onivyde
              • Key Results from Select Clinical Trials Investigating Onivyde for the Treatment of Pancreatic Adenocarcinoma
              • Ongoing Clinical Development of Onivyde
              • Key Ongoing Clinical Trials of Onivyde in the Treatment of Pancreatic Adenocarcinoma
              • Expert Insight: Onivyde
              • Advantages and Disadvantages of Tarceva
              • Ongoing Clinical Development of Tarceva
              • Key Ongoing Clinical Trials of Tarceva in the Treatment of Pancreatic Adenocarcinoma
              • Expert Insight: Tarceva
              • Advantages and Disadvantages of Keytruda
              • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of Pancreatic Cancer
              • Ongoing Clinical Development of Keytruda
              • Key Ongoing Clinical Trials of Keytruda in the Treatment of Pancreatic Cancer
              • Expert Insight: Keytruda
              • Key Results of Select Clinical Trials Investigating Lynparza for the Treatment of Pancreatic Adenocarcinoma
              • Ongoing Clinical Development of Lynparza
              • Key Ongoing Clinical Trials of Lynparza in the Treatment of Pancreatic Cancer
              • Expert Insight: Lynparza
              • Advantages and Disadvantages of Somatuline Autogel/Depot
              • Ongoing Clinical Development of Somatuline Autogel/Depot
              • Expert Insight: Somatuline Autogel/Depot
              • Advantages and Disadvantages of Lutathera
              • Key Results from Select Clinical Trials Investigating Lutathera for the Treatment of Pancreatic Neuroendocrine Tumors
              • Ongoing Clinical Development of Lutathera
              • Expert Insight: Lutathera
              • Advantages and Disadvantages of Afinitor
              • Ongoing Clinical Development of Afinitor
              • Key Ongoing Clinical Trials of Afinitor in the Treatment of Pancreatic Neuroendocrine Tumors
              • Expert Insight: Afinitor
              • Advantages and Disadvantages of Sutent
              • Expert Insight: Sutent
            • Medical Practice
              • Pancreatic Cancer: Resectable (Stage I-IIB)
              • Pancreatic Cancer: Unresectable (Stage III) and Metastatic (Stage IV), First-Line
              • Pancreatic Cancer: Metastatic, Second-Line
              • Pancreatic Neuroendocrine Tumors: Resectable (Stage I-II)
              • Pancreatic Neuroendocrine Tumors: Unresectable (Stage III) and Metastatic (Stage IV), First-Line
              • Pancreatic Neuroendocrine Tumors: Metastatic, Second-Line
              • Pancreatic Adenocarcinoma Treatment Guidelines
              • Pancreatic Neuroendocrine Tumors Treatment Guidelines
              • Patient Characteristics Influencing Drug Selection in Pancreatic Cancer
              • Treatment Decision Tree for Pancreatic Adenocarcinoma: United States
              • Treatment Decision Tree for Pancreatic Neuroendocrine Tumors: United States
              • Treatment Decision Tree for Pancreatic Adenocarcinoma: Europe
              • Treatment Decision Tree for Pancreatic Neuroendocrine Tumors: Europe
              • Treatment Decision Tree for Pancreatic Adenocarcinoma: Japan
              • Treatment Decision Tree for Pancreatic Neuroendocrine Tumors: Japan
          • Unmet Need
            • Current and Future Attainment of Unmet Needs in Pancreatic Cancer
            • Expert Insight on Unmet Needs in the Treatment of Pancreatic Cancer
            • Top Unmet Needs in the Treatment of Pancreatic Cancer—Current and Future Attainment
          • Emerging Therapies
            • Key Findings
              • Pipeline Trends in Pancreatic Cancer
            • Key Emerging Therapies
              • Notable Developments Among Key Emerging Therapies for Pancreatic Cancer
              • Key Therapies in Development for Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Glufosfamide for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Glufosfamide in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Glufosfamide
              • Expert Insight: Glufosfamide
              • Expectations for Market Authorization and Sales Opportunity for Glufosfamide in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Masiviera for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Masiviera in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Masiviera
              • Expert Insight: Masiviera
              • Expectations for Market Authorization and Sales Opportunity of Masiviera in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Vaccell for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Vaccell in the Treatment of Pancreatic Cancer
              • Expert Insight: Use of Vaccell in the Treatment of Pancreatic Cancer
              • Expert Insight: Vaccell
              • Expectations for Market Authorization and Sales Opportunity for Vaccell in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Pamrevlumab for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Pamrevlumab in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Pamrevlumab
              • Expert Insight: Pamrevlumab
              • Expectations for Market Authorization and Sales Opportunity of Pamrevlumab in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Nanoplatin for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Nanoplatin in the Treatment of Pancreatic Cancer
              • Nanoplatin Clinical Development
              • Expert Insight: Use of Nanoplatin in the Treatment of Pancreatic Cancer
              • Expectations for Market Authorization and Sales Opportunity for Nanoplatin in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Devimistat for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Devimistat in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Devimistat (CPI-613)
              • Expert Insight: Devimistat (CPI-613)
              • Expectations for Market Authorization and Sales Opportunity for Devimistat in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating Eryaspase for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of Eryaspase in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for Eryaspase (GRASPA)
              • Expert Insight: Eryaspase (GRASPA)
              • Expectations for Market Authorization and Sales Opportunity of Eryaspase in Pancreatic Cancer
              • Key Results of Select Clinical Trials Investigating SM-88 (Racemetyrosine) for the Treatment of Pancreatic Cancer
              • Key Ongoing Clinical Trials of SM-88 (Racemetyrosine) in the Treatment of Pancreatic Cancer
              • Analysis of the Clinical Development Program for SM-88 (Racemetyrosine)
              • Expert Insight: SM-88 (Racemetyrosine)
              • Expectations for Market Authorization and Sales Opportunity of SM-88 (Racemetyrosine) in Pancreatic Cancer
            • Early-Phase Pipeline Analysis
              • Select Compounds in Early-Phase Development for Pancreatic Cancer
            • Key Discontinuations and Failures in Pancreatic Cancer
              • Key Discontinuations and Failures
          • Access & Reimbursement
            • Region-Specific Reimbursement Practices
              • Key Market Access Considerations in Pancreatic Cancer: United States
              • General Reimbursement Environment: United States
              • Key Market Access Considerations in Pancreatic Cancer: EU5
              • General Reimbursement Environment: EU5
              • Key Market Access Considerations in Pancreatic Cancer: Japan
              • General Reimbursement Environment: Japan
            • Looking for More?
          • Appendix
            • Key Abbreviations Related to Pancreatic Cancer
            • Brands, Marketers, and Generic Availability of Key Therapies for Pancreatic Cancer, by Market
            • Pancreatic Cancer Bibliography

        Author(s): Ananya Sadhu, Ph.D.; Laura Vinuesa, D.V.M., M.Sc.

        Ananya Sadhu, Ph.D., is an analyst on the Oncology team at DRG, part of Clarivate. She is primarily responsible for pancreatic cancer content and client support. She has authored several syndicated reports and forecasts for the pancreatic cancer therapy market. Prior to joining DRG, she was a postdoctoral fellow at the National Centre of Biological Sciences in Bangalore, where she studied the role of chromatin architecture in regulating gene expression in breast cancer. She also worked as a scientific officer at Arvind Remedies, where she coordinated various stages of nonclinical / clinical research activities for drug development of a patented polyherbal formulation. She holds a Ph.D. in molecular biology from the National Institute of Immunology in New Delhi.

        Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at DRG, part of Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously at DRG, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master's degree in clinical research and pharmaceutical medicine from EPHOS, School of PharmaStudies, in Madrid.